miRNA与甲状腺癌发病的研究现状  

Research Status on miRNA and Thyroid Cancer Onset

作　　者：谢靖[1] 王旭[2] XIE Jing;WANG Xu(Nanjing University of Chinese Medicine ,Nanjing 210023,China;Jiangsu Province Hospital of Chinese Medicine,Nanjing 210046,China)

机构地区：[1]南京中医药大学,南京210023 [2]江苏省中医院内分泌科,南京210046

出　　处：《医学综述》2019年第19期3818-3822,3827,共6页Medical Recapitulate

基　　金：江苏省自然科学基金(BK20151572)

摘　　要：甲状腺癌是由机体碘缺乏、辐射、遗传等因素引起的最常见的恶性肿瘤之一,其具体的发病机制目前尚不清楚。微RNA(miRNA)可以调控相关的信号通路,调控甲状腺癌细胞的生物学行为,参与甲状腺癌的发生发展。miRNA在甲状腺癌中的差异表达与临床病理特征有关,在甲状腺癌的临床诊断、治疗和预后中均有一定的应用价值。深入研究总结miRNA与甲状腺癌发病之间的关系,可以为甲状腺癌的分子诊断、靶向治疗及预后预测提供一定的基础。Thyroid cancer is one of the most common malignant tumors caused by iodine deficiency,radiation,heredity and other factors.MicroRNA(miRNA) can regulate the biological behavior of thyroid cancer cells by regulating relevant signaling pathways,and plays an important role in the occurrence and development of thyroid cancer.The differential expression of miRNA in thyroid cancer is related to its clinicopathological characteristics,which has certain applicative value in the clinical diagnosis,treatment and prognosis of thyroid cancer.Deeper understanding of the relationship between miRNA and thyroid cancer occurrence can provide a basis for the molecular diagnosis,targeted therapy and prognosis prediction of thyroid cancer.

关 键 词：微RNA 乳头状甲状腺癌 滤泡状甲状腺癌 未分化型甲状腺癌 甲状腺髓样癌 

分 类 号：R363.2[医药卫生—病理学]